Next Article in Journal
Simultaneous Nasal Carriage by Methicillin-Resistant and Methicillin Susceptible Staphylococcus aureus of Lineage ST398 in a Live Pig Transporter
Previous Article in Journal
Vaccinia Virus as a Master of Host Shutoff Induction: Targeting Processes of the Central Dogma and Beyond
Previous Article in Special Issue
A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population
Open AccessArticle

Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts

1
Division of Pediatric Infectious Diseases, Boston Medical Center, Boston, MA 02118, USA
2
Boston University Schools of Medicine, Boston, MA 02118, USA
3
Boston University School of Public Health, Boston Medical Center, Boston, MA 02118, USA
4
Division of Pediatric Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA
5
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA
6
Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA
7
Massachusetts Department of Public Health, 250 Washington St, Boston, MA 02108, USA
*
Author to whom correspondence should be addressed.
Pathogens 2020, 9(5), 396; https://doi.org/10.3390/pathogens9050396
Received: 18 April 2020 / Revised: 5 May 2020 / Accepted: 18 May 2020 / Published: 21 May 2020
(This article belongs to the Special Issue Development of Pneumococcal Vaccines for the World)
Background: Although a substantial decline in vaccine-serotype invasive pneumococcal disease (IPD) incidence was observed following the introduction of pneumococcal conjugate vaccines (PCV), the estimated range of thirteen-valent conjugate vaccine (PCV13) effectiveness for serotype 3 disease is wide and includes zero. We assessed the impact of PCV13 on serotype 3 IPD incidence and disease characteristics in Massachusetts’ children. Methods: Serotype 3 IPD cases in children <18 years old were identified via enhanced passive surveillance system in Massachusetts. We compared incidence rates and characteristics of IPD cases before and after PCV13. Results: A total of 47 serotype 3 IPD cases were identified from 2002 to 2017; incidence of serotype 3 IPD in the years following PCV13 was 0.19 per 100,000 children compared to 0.21 before PCV 13, incidence rate ratio (IRR) = 0.86 (95% CI 0.47–1.57). The majority (78%) of post-PCV13 serotype 3 IPD cases occurred among fully vaccinated children. Age distribution, clinical syndrome and presence of comorbidities among serotype 3 IPD cases were similar before and after PCV13 introduction. There was no association between the date of the last PCV13 dose and time to IPD to suggest waning of immunity. Conclusions: seven years following PCV 13 we found no significant changes in serotype 3 IPD incidence or disease characteristics in children in Massachusetts. View Full-Text
Keywords: Streptococcus pneumoniae serotype 3; PCV13; invasive pneumococcal disease Streptococcus pneumoniae serotype 3; PCV13; invasive pneumococcal disease
Show Figures

Figure 1

MDPI and ACS Style

Lapidot, R.; Shea, K.M.; Yildirim, I.; Cabral, H.J.; Pelton, S.I.; Department of Public Health, M. Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts. Pathogens 2020, 9, 396.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop